A polipoprotein C-I (apoC-I), a 6.6-kDa plasma protein, has a basic pI because of its high content of lysine (16 mol %) and contains no histidine, tyrosine, cysteine, or carbohydrate. 1, 2 Residues 7 to 24 and 35 to 53 of apoC-I are important for binding to plasma lipids. 1, 2 ApoC-I is a component of very-low-density (VLDL), intermediate density, and high-density lipoproteins (HDL). ApoC-I displaces apolipoprotein E (apoE) from VLDL and intermediate density, thereby decreasing their clearance from plasma. 3 ApoC-I decreases the binding of ␤-VLDL to a remnant receptor, the low-density lipoprotein (LDL) receptor-related protein (LRP), 4, 5 and apoE-mediated binding of VLDL and intermediate density to the LDL receptor (LDLR). 6, 7 ApoC-I inhibits cholesterol ester transfer protein 8 and phospholipase A2 activity. 9 ApoC-I stimulates lecithin cholesterol acyl transferase to Ϸ80% of that of apolipoprotein A-I (apoA-I). 10 Human apoC-I-transgenic mice, with a wild-type background or with a knockout background for the LDLR or apoE, manifest a marked combined hyperlipidemia because of significantly delayed remnant clearance. [11] [12] [13] [14] [15] [16] [17] Free fatty acid levels are elevated because of reduced fatty acid uptake in peripheral tissues, which is an effect that is paradoxically associated with increased sensitivity to insulin and protection from obesity. 12, 13 Of particular interest here, Conde-Knape et al, 17 using a moderately expressing apoC-I transgenic on apoE-null background to study the effect of apoC-I independent of apoE, found a marked combined dyslipidemia that included an apoC-I-enriched HDL and increased atherosclerosis. ApoC-I-enriched HDL (but not VLDL) had a marked inhibitory effect on hepatic lipase. 17 ApoC-I knockouts are normolipidemic rather than hypolipidemic. 18 Cholesterol ester transfer protein-transgenic/apoC knockout mice manifest a markedly increased transfer of cholesteryl esters from HDL to VLDL. 19 In humans, Bjorkegren et al reported a significant enrichment of apoC-I in VLDL remnants in normolipidemic patients with coronary artery disease and exaggerated postprandial triglyceridemia 20 and in healthy, normolipidemic men with early asymptomatic atherosclerosis. 21 Because low-birth-weight is associated with increased risk for and death from cardiovascular disease in adults, 22 we examined lipoprotein heterogeneity at birth in cord blood (unpublished data). We found, in agreement with others, that a significant proportion of infants had increased levels of large HDL particles [23] [24] [25] but, in addition, these particles were enriched with apoC-I. In pilot experiments, it was found that the apoC-I-enriched HDL, as well as highly purified apoC-I, promoted apoptosis in cultured human aortic smooth muscle cells (ASMC).
ASMC play a critical role in preventing the complications of atherosclerosis as part of the fibrous cap that sequesters the lipid core and prevents plaque rupture. 26 We report that purified apoC-I alone, and immunoaffinity purified apoC-Ienriched HDL particles, induces marked apoptosis in cultured human ASMC. Moreover, the mechanism of action of apoC-I appears to be mediated through the recruitment of N-SMase, generating ceramide and activating cytochrome c release as well as caspase. We speculate that this biochemical mechanism by which apoC-I promotes apoptosis in ASMC may contribute to an unstable plaque that is more likely to rupture, leading to thrombosis, myocardial infarction, and death. 26
Methods
Please see online Methods, available at http://atvb.ahajournals.org.
Results

ApoC-I and ApoC-I-Enriched HDL Particles Stimulate Apoptosis in ASMC
Cells incubated with apoC-I contained many apoptotic cells, as judged by white staining of the nucleus after treatment with 4Ј, 6-diamidino-2-phenylindole dihydrochloride (DAPI) reagent ( Figure 1A) . In contrast, cells incubated with apoC-III for 24 hours had only a few apoptotic cells ( Figure 1A ). After fluorescence microscopic quantitative analysis of DAPI staining of the nucleus in attached cells after treatment ( Figure 1B ), 2.24% of normal (control) cells, 4.78% of apoC-III-treated cells, and 26.19% of apoC-I-treated cells were apoptotic. In addition, Ϸ50% of ASMC incubated with apoC-I-enriched HDL particles were apoptotic; whereas only Ϸ2% of the cells incubated with apoC-I-poor HDL were apoptotic ( Figure 1B ; Table 1 ).
Apoptotic cells undergo endonucleosomal cleavage, resulting in the fragmentation of DNA into 180 to 200 base-pair fragments that resolve as a ladder on agarose gel electrophoresis. Cells incubated with tumor necrosis factor ␣ (TNF-␣) (positive control), or with apoC-I, exhibited DNA laddering. In contrast, control cells, and those incubated with apoC-III, did not exhibit significant DNA laddering ( Figure 1C ).
Neutral Sphingomyelinase Inhibitor, GW4869, Abrogates ApoC-I-Induced Apoptosis
As shown in Figure 2A and the corresponding densitometric scan ( Figure 2B ), N-SMase inhibitor, GW4869 (20 mol/L), completely abrogated the apoC-1-induced apoptosis (Ϸ12% compared with control Ϸ2%), an effect that was also observed using a lower dose (10 mol/L) of GW4869. However, when C2-ceramide was added to the ASMC with apoC-I and GW4869, the inhibitory effect of GW4869 on N-SMAse was bypassed and apoptosis was restored (Figure 2A and B) (Ϸ12.5% of apoptotic cells compared with control of 2.2% apoptotic cells).
ApoC-I and ApoC-I-Enriched HDL Particles Stimulate the Activity of N-SMase in Cultured ASMC
Within 5 minutes of incubation of cells with TNF-␣ (positive control) and apoC-I, there was Ϸ2-fold increase in the activity of N-SMase that reached a maximum at 10 minutes and then decreased to baseline by 30 to 60 minutes ( Figure  3A ). Such a pattern was not seen in the control cells or in those incubated with apoC-III. The stimulation of N-SMase activity with apoC-I-enriched HDL particles was even more pronounced than that seen with TNF-␣ and apoC-I ( Figure  3B ). At 5 minutes, there was a 2.6-fold stimulation of activity of N-SMase that reached a maximum of 2.7-fold stimulation at 10 minutes. In contrast to TNF-␣ and apoC-I, the stimu-
Effect of apolipoproteins on apoptosis in human ASMC. ASMC were grown on sterilized glass cover slips and incubated for 24 hours with media alone (control), apoC-III (negative control, 2.5 g/mL medium), apoC-I (2.5 g/mL medium), apoC-I-enriched HDL (1 g apoA-I/mL medium), or apoC-Ipoor HDL (5 g apoA-I/mL medium) for 24 hours. Cells were then fixed with ethanol-acetic acid (3:1 volume/volume) and washed 3 times with phosphate-buffered saline. The cells were then stained with DAPI reagent, mounted on a glass cover slide, and subjected to fluorescence microscopy. A, The nucleus of normal cells stains blue and the nucleus of apoptotic cells stains is fragmented white. B, Ϸ300 to 500 cells in each sample were counted and the percent of apoptotic cells was plotted. Values are meanϮSD; **PϽ0.01, ***PϽ0.001. C, DNA ladder assay. Confluent cultures of ASMC were incubated with control medium alone, apoC-I (2.5 g/mL medium), apoC-III (negative control, 2.5 g/mL medium), and TNF-␣ (positive control, 20 ng/mL medium). Genomic DNA was extracted and 10 g DNA was subjected to agarose gel electrophoresis. The gels were calibrated with commercially available DNA standards. After electrophoresis, the gels were stained with ethidium bromide and then photographed. lation of N-SMase activity with apoC-I-enriched HDL was still manifested (2.2-fold) at 30 minutes and then approached baseline at 60 minutes ( Figure 3B ). ApoC-I-poor HDL also stimulated N-SMase activity in a similar pattern, but to a considerably lesser extent than apoC-I-enriched HDL (Figure 3B ). ApoC-I exerted a concentration-dependent increase in the activity of N-SMase in ASMC ( Figure 3C) , with a maximum increase in N-SMase activity (1.5-fold) at a concentration of apoC-I of 2.5 g/mL medium). In additional experiments to examine the specificity of this inhibitor, we found that GW4869 did not alter the acid sphingomyelinase activity (control: 400 nmol/mg protein; GW4869: 340 nmol/mg protein) in cultured human ASMC.
Antibody Against N-SMase Abrogates apoC-I-Enriched HDL-Induced N-SMase Activity in Cultured ASMC
Previous studies in human renal proximal tubular cells 27 and neuronal cells 28 have shown that N-SMase is localized on the outer leaflet of plasma membrane. Using N-SMase antibody and FITC-conjugated secondary antibody, we made similar observations in human ASMC (data not shown). We therefore preincubated ASMC with an antibody (IgG) against N-SMase (1:500 dilution) and found that anti-N-SMase, but not rabbit IgG (control), inhibited the stimulation of N-SMase activity minutes with serum-free (control) medium, then apoC-I (2.5 g/mL medium), apoC-III (2.5 g/mL medium), TNF-␣ (20 ng/mL medium) (A, top), or apoC-I-enriched HDL (1 g apoA-I/mL medium), or apoC-I-poor HDL (5 g apoA-I/mL medium) (B, middle) were added individually to cells. The cells were then incubated and harvested at the indicated time points, and the activity was of N-SMase determined using 14 C sphingomyelin as substrate (see Methods). The N-SMase activity in control cells was 22 nmol/h per milligram cell protein and this value was considered as 100% activity. In a separate experiment (C, bottom), cells (0.5 ϫ 10 5) were seeded in P60 Petri dishes and grown in DMEM supplemented with 10% fetal bovine serum for 5 days. After preincubation of cells for 30 minutes in serum-free medium, increasing amounts of apoC-I were added. After incubation for 10 minutes, cells were harvested and N-SMase activity measured as described in Methods.
by apoC-I-enriched HDL by 77%. This result suggested that apoC-I mediated the increased activity of N-SMase in human ASMC by the apoC-I-enriched HDL particle at the cell surface.
ApoC-I and ApoC-I-Enriched HDL Particles Stimulate the Generation of Ceramide in Cultured Human ASMC
ApoC-I exerted a time-dependent increase in ceramide levels, which reached a maximum effect (1.7-fold) by 5 minutes and then decreased to a value similar to that in control cells by 10 minutes ( Figure 4A ). Incubation of ASMC with apoC-Ienriched HDL particles with time reached a maximum increase (Ϸ1.7-fold) in the level of ceramide by 30 minutes, compared with control cells, whereas apoC-I-poor HDL only stimulated the ceramide level slightly ( Figure 4B ). GW4869 (20 mol/L) significantly decreased the cellular level of ceramide induced by apoC-I after 5 minutes and 6 hours of incubation. GW4869 completely inhibited apoC-I-induced ceramide production after 12 hours of incubation but reversed it to a high level 24 hours later ( Figure 4C ). Using an anti-ceramide antibody, cells treated with apoC-I reacted strongly, as judged by immunofluorescence microscopy, compared with control cells ( Figure 4D ). Most fluorescence was localized in the perinuclear area, an effect of apoC-I on the ceramide level that was eliminated by GW 4869, an inhibitor of N-SMase.
ApoC-I and ApoC-I-Enriched HDL Particles Stimulate the Release of Cytochrome c From Mitochondria in ASMC
The release of cytochrome c from mitochondria into cytosol is a key pro-apoptotic event. ApoC-I stimulated the release of cytochrome c 4.1-fold. ApoC-III and apoC-I-enriched HDL particles also showed some stimulation of cytochrome c (2.3and 1.2-fold, respectively) ( Figure 5A and B) . Using immunofluorescence, a marked increase in the release of cytochrome c from mitochondria into the cytoplasm with apoC-I (even greater than that with TNF-␣) was noted, an effect that was inhibited by GW4869 ( Figure 5C ).
ApoC-I and ApoC-I-Enriched HDL Particles Stimulate the Expression of Caspase-3 in Human ASMC
ApoC-I stimulated the caspase-3 level 4-fold compared with control medium. ApoC-I-enriched HDL stimulated caspase-3 expression in ASMC 1.7-fold, whereas apoC-Ipoor HDL did not. ApoC-III also stimulated caspase-3 expression, but to a lesser extent than apoC-I-enriched HDL (data not shown).
Discussion
The most striking phenotypic change in ASMC treated with apoC-I or apoC-I-enriched HDL particles was apoptosis that accompanied the activation of the sphingomyelinase signal transduction cascade. In additional studies, we observed that apoC-I induced the expression of Lyn-kinase protein (data not shown). Moreover, TNF-␣-induced N-SMase activation in ASMC was inhibited by the use of tyrosine kinase inhibitors. Therefore, we postulate that by stimulating one or more membrane-bound protein kinases, apoC-I may activate N-SMase in human ASMC. Both apoC-I and apoC-I-enriched HDL particles stimulated the activity of N-SMase in ASMC in a time-and concentration-dependent fashion. Moreover, the kinetics of N-SMase activation by these two agonists was similar to that of TNF-␣, in this study and in our previous studies. 29 The tenet that apoC-I induced N-SMase activation and the subsequent production of ceramide were essential steps in the signaling cascade leading to apoptosis was substantiated by the following: (1) N-SMase inhibitor, GW4869, abrogated apoC-I-induced ceramide generation, cytochrome c release, and apoptosis; (2) preincubation of cells with antibody against N-SMase (but not the control rabbit IgG) prevented apoC-I-induced N-SMase activation and apoptosis; (3) incubation of cells with apoC-III, which has some structural homology with apoC-I, did not stimulate N-SMase activation and apoptosis; and (4) incubation of cells with apoC-I-poor HDL particles did not elevate N-SMase activity and apoptosis to the same extent as apoC-I-enriched HDL. These studies were performed in vitro, and future After addition of apoC-I (2.5 g/mL), incubation was continued for 6 hours, 12 hours, and 24 hours. After incubation cells were harvested and the levels of ceramide determined using the diacylglycerol kinase assay (see Methods). The level of phosphate was measured and the data (meanϮSD) were expressed as percentage of the total ceramide present in untreated cells (vehicle DMSO). *PϽ0.05. In a separate experiment (D, right), confluent cells were grown on cover slips and pretreated with serum-free medium for 30 minutes. The cells were then incubated with vehicle DMSO alone (control), apoC-I (2.5 g/mL), or apoC-I (2.5 g/mL) plus the N-SMase inhibitor, GW4869 (20 mol/L), for 24 hours. The cells were then washed, treated with a primary anticeramide antibody, washed with phosphate-buffered saline, and treated with a fluorescein isothiocyanate-conjugated anti-mouse IgG as described in Methods (C, lower panel). studies will be necessary to determine the effect of apoC-I on ASMC in vivo.
Recently, the use of GW4869, an N-SMase inhibitor, was shown in human breast cancer cells, MCF-7, to reduce agonist (TNF-␣)-induced apoptosis. 30 Using molecular cloning, this inhibitor was shown to be a target for N-SMase. 31 Furthermore, recombinant acid sphingomyelinase activity and the activity of serine palmitoyltransferase (SPT) involved in de novo ceramide biosynthesis were shown to be unaffected in MCF-7 cells by GW4869 treatment. 30 In addition, we also found that GW4869 does not alter the acid sphingomyelinase activity in cultured human ASMC. In our study, GW4869 (at 10 mol/L and 20 mol/L) completely inhibited apoC-I-induced apoptosis and apoC-I-induced ceramide generation ( Figure 4C and D) , suggesting that apoC-I may preferentially activate N-SMase to generate ceramide and induce apoptosis. Moreover, the increase in the cell level of ceramide after 24 hours of treatment with either apoC-I or GW4869 suggests that by this time, this inhibitor no longer prevented the apoC-I-induced increase in the cell ceramide level. Our findings in human ASMC are similar to those published by others using breast cancer cells. 30 Clearly, additional studies are necessary to delineate further the biochemical pathways by which apoC-I can generate ceramide and induce apoptosis.
HDL particles contain several other apolipoproteins, as well as lipids, in addition to apoC-I (Table 1) . We therefore cannot exclude the possibility that other apolipoprotein and lipid moieties, independently or collectively, contribute to N-SMase activation and apoptosis. In addition, the presence of oxidized cholesterol in caveolae may activate a signaling pathway leading to apoptosis. 32 However, our studies included a control, namely immunoaffinity-purified apoC-Ipoor HDL particles, whose lipid composition was quite similar to that of the immunoaffinity-purified apoC-I-enriched HDL (Table 1) .
Although several studies point to the role of oxidized LDL and its components in inducing apoptosis in cells of the vascular wall, little is known about various apolipoproteins and their effect on apoptosis. Our previous study showed that apolipoproteins B, A-I, A-II, and E did not alter apoptosis in cultured human ASMC. Only very high doses of LDL (Ͼ200 g/mL medium) induced cell death, an action mostly caused by a necrotic/cytotoxic effect. HDL had either no effect on cell death or rescued cells from LDL induced necrosis. 33, 34 In humans, apoC-I may be atherogenic by delaying the receptor-mediated uptake of remnants from triglyceride-rich lipoproteins. 20, 21 Based on our present report, we postulate that increased plasma levels of apoC-I, perhaps associated with HDL, might also contribute to the complications of atherosclerosis by inducing apoptosis in ASMC, a biochem- After treatment of confluent cells for 24 hours with apoC-I (2.5 g/mL medium), apoC-III (2.5 g/mL medium), or apoC-I-enriched HDL (1 g apoA-I/mL medium), the cells were lysed. The cell lysates was used as the source of cytochrome c, and the pellet was used as a source of caspase-3. The cell lysates were separated by SDS-polyacrylamide gel electrophoresis, blotted onto nitrocellulose, and cytochrome c detected using a polyclonal antibody against cytochrome c (A, top panel). The gels were then subjected to densitometric scanning (B, middle panel). In a separate experiment (C, right), confluent cells were grown on cover slips and pretreated with serum-free medium for 30 minutes. The cells were then incubated with control medium, apoC-I (2.5 g/mL medium), TNF-␣ (20 ng/mL), or apoC-I (2.5 g/mL) ϩ GW4869 (20 mol/L) for 24 hours. The cells were then washed, treated with a primary anti-cytochrome c antibody, washed with phosphate-buffered saline, and treated with a fluorescein isothiocyanate-conjugated anti-rabbit IgG as described in Methods (C, lower panel). ApoC-I-enriched HDL and apoC-I-poor HDL were isolated from the heparin manganese supernatants of human plasma from umbilical cord blood by immunoaffinity chromatography as described in Methods. ApoC-I-enriched HDL is the apoA-II-retained, apoC-I-retained fraction of LpA-I:A-II particles. ApoC-poor HDL is the apoA-II-retained, apoC-I-unretained fraction of LpA-I:A-II particles.
Lipid and Apolipoprotein Composition of ApoC-Enriched HDL and ApoC-I-Poor HDL
